Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLLS | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 270.7M |
| IPO Year | 2014 | 2017 |
| Metric | CLLS | PROF |
|---|---|---|
| Price | $3.27 | $5.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $12.00 |
| AVG Volume (30 Days) | 43.9K | ★ 256.9K |
| Earning Date | 03-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $40.37 | $115.41 |
| Revenue Next Year | N/A | $60.63 |
| P/E Ratio | ★ N/A | $3.65 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $1.10 | $3.90 |
| 52 Week High | $5.48 | $8.95 |
| Indicator | CLLS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 31.81 |
| Support Level | $3.32 | $4.09 |
| Resistance Level | $3.83 | $5.96 |
| Average True Range (ATR) | 0.21 | 0.51 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 15.54 | 6.34 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.